Fmr LLC Has $40.35 Million Position in Calithera Biosciences, Inc. (CALA)

Fmr LLC boosted its holdings in shares of Calithera Biosciences, Inc. (NASDAQ:CALA) by 85.8% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,717,090 shares of the biotechnology company’s stock after buying an additional 1,254,900 shares during the period. Fmr LLC owned approximately 7.70% of Calithera Biosciences worth $40,349,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also made changes to their positions in the stock. Vanguard Group Inc. increased its position in Calithera Biosciences by 29.7% during the 2nd quarter. Vanguard Group Inc. now owns 1,199,525 shares of the biotechnology company’s stock valued at $17,813,000 after buying an additional 274,510 shares in the last quarter. Northern Trust Corp increased its position in Calithera Biosciences by 1,355.1% during the 2nd quarter. Northern Trust Corp now owns 337,640 shares of the biotechnology company’s stock valued at $5,014,000 after buying an additional 314,436 shares in the last quarter. Citigroup Inc. increased its position in Calithera Biosciences by 5,957.9% during the 2nd quarter. Citigroup Inc. now owns 42,405 shares of the biotechnology company’s stock valued at $630,000 after buying an additional 41,705 shares in the last quarter. GSA Capital Partners LLP increased its position in Calithera Biosciences by 187.2% during the 2nd quarter. GSA Capital Partners LLP now owns 81,357 shares of the biotechnology company’s stock valued at $1,208,000 after buying an additional 53,027 shares in the last quarter. Finally, Artal Group S.A. acquired a new position in Calithera Biosciences during the 2nd quarter valued at about $2,970,000. 71.88% of the stock is currently owned by institutional investors.

Several brokerages recently issued reports on CALA. BidaskClub lowered Calithera Biosciences from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 12th. William Blair began coverage on Calithera Biosciences in a research report on Thursday, October 5th. They set an “outperform” rating on the stock. Finally, Zacks Investment Research lowered Calithera Biosciences from a “buy” rating to a “hold” rating in a research report on Thursday, July 13th. One research analyst has rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $15.50.

In other Calithera Biosciences news, major shareholder Adage Capital Partners Gp, L.L sold 576,000 shares of Calithera Biosciences stock in a transaction dated Thursday, September 28th. The stock was sold at an average price of $15.64, for a total transaction of $9,008,640.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 16.30% of the stock is owned by insiders.

COPYRIGHT VIOLATION NOTICE: This report was originally posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this report on another publication, it was illegally copied and republished in violation of U.S. and international trademark and copyright laws. The original version of this report can be accessed at https://ledgergazette.com/2017/10/19/fmr-llc-has-40-35-million-position-in-calithera-biosciences-inc-cala.html.

Calithera Biosciences, Inc. (NASDAQ CALA) opened at 17.60 on Thursday. Calithera Biosciences, Inc. has a 12 month low of $2.20 and a 12 month high of $20.05. The firm’s market capitalization is $624.38 million. The company’s 50-day moving average price is $16.28 and its 200 day moving average price is $14.79.

Calithera Biosciences (NASDAQ:CALA) last announced its quarterly earnings results on Tuesday, August 8th. The bi

A number of other large investors have also made changes to their positions in the stock. Vanguard Group Inc. increased its position in Calithera Biosciences by 29.7% during the 2nd quarter. Vanguard Group Inc. now owns 1,199,525 shares of the biotechnology company’s stock valued at $17,813,000 after buying an additional 274,510 shares in the last quarter. Northern Trust Corp increased its position in Calithera Biosciences by 1,355.1% during the 2nd quarter. Northern Trust Corp now owns 337,640 shares of the biotechnology company’s stock valued at $5,014,000 after buying an additional 314,436 shares in the last quarter. Citigroup Inc. increased its position in Calithera Biosciences by 5,957.9% during the 2nd quarter. Citigroup Inc. now owns 42,405 shares of the biotechnology company’s stock valued at $630,000 after buying an additional 41,705 shares in the last quarter. GSA Capital Partners LLP increased its position in Calithera Biosciences by 187.2% during the 2nd quarter. GSA Capital Partners LLP now owns 81,357 shares of the biotechnology company’s stock valued at $1,208,000 after buying an additional 53,027 shares in the last quarter. Finally, Artal Group S.A. acquired a new position in Calithera Biosciences during the 2nd quarter valued at about $2,970,000. 71.88% of the stock is currently owned by institutional investors.

Several brokerages recently issued reports on CALA. BidaskClub lowered Calithera Biosciences from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 12th. William Blair began coverage on Calithera Biosciences in a research report on Thursday, October 5th. They set an “outperform” rating on the stock. Finally, Zacks Investment Research lowered Calithera Biosciences from a “buy” rating to a “hold” rating in a research report on Thursday, July 13th. One research analyst has rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $15.50.

In other Calithera Biosciences news, major shareholder Adage Capital Partners Gp, L.L sold 576,000 shares of Calithera Biosciences stock in a transaction dated Thursday, September 28th. The stock was sold at an average price of $15.64, for a total transaction of $9,008,640.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 16.30% of the stock is owned by insiders.

COPYRIGHT VIOLATION NOTICE: This report was originally posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this report on another publication, it was illegally copied and republished in violation of U.S. and international trademark and copyright laws. The original version of this report can be accessed at https://ledgergazette.com/2017/10/19/fmr-llc-has-40-35-million-position-in-calithera-biosciences-inc-cala.html.

Calithera Biosciences, Inc. (NASDAQ CALA) opened at 17.60 on Thursday. Calithera Biosciences, Inc. has a 12 month low of $2.20 and a 12 month high of $20.05. The firm’s market capitalization is $624.38 million. The company’s 50-day moving average price is $16.28 and its 200 day moving average price is $14.79.

Calithera Biosciences (NASDAQ:CALA) last announced its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.29) by $0.14. The business had revenue of $7.26 million for the quarter, compared to analysts’ expectations of $4.80 million. Analysts predict that Calithera Biosciences, Inc. will post ($0.81) EPS for the current year.

Calithera Biosciences Profile

Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.

Institutional Ownership by Quarter for Calithera Biosciences (NASDAQ:CALA)

Receive News & Ratings for Calithera Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply